Anzeige
Mehr »
Montag, 09.02.2026 - Börsentäglich über 12.000 News
Der Shakeout: Silber hat genau das getan, was echte Bullenmärkte immer tun - es hat die Touristen abgeschüttelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
28 Leser
Artikel bewerten:
(0)

National Survey Shows Physicians Have Clear Preference Between the Two Largest Diagnostic Laboratories


LYNDHURST, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated , the leading provider of diagnostic testing, information and services, announced today results of a national physician study on preference and performance of medical laboratory services. When physicians were asked which of the two largest national laboratories they preferred, the majority of physicians expressed a preference. Those with a preference overwhelmingly chose Quest Diagnostics over Laboratory Corporation of America Holdings (LabCorp). National Analysts Worldwide, a respected market research firm, conducted the survey among a nationally representative sample of general practitioners, family practitioners, internists and obstetrician/gynecologists that have had experience with both Quest Diagnostics and LabCorp over the past six months.

"I am pleased that the national survey shows that when it comes to the two largest diagnostic laboratories, physicians overwhelmingly prefer Quest Diagnostics," said Surya N. Mohapatra, Ph.D., Chairman and CEO of Quest Diagnostics. "We are in the medical business and our reputation rests on service and quality. That's why we are committed to providing a differentiated level of service to meet the requirements of our customers."

Physicians also were asked to rate Quest Diagnostics and LabCorp on 11 key elements of laboratory service. Quest Diagnostics outscored LabCorp on every measure.


"The magnitude of the preference for Quest Diagnostics in this survey is very impressive. So often, market researchers can detect only the subtlest of differentiation between major brands in a marketplace," said Susan Schwartz McDonald, Ph.D., CEO of National Analysts, which conducted the survey on behalf of Quest Diagnostics. "Seldom do we see the kind of consistent, significant, and vivid differentiation displayed in these data. It's apparent that many physicians have a lot of conviction about Quest Diagnostics, and that conviction is based on a broad-ranging assessment of Quest's performance."

About National Analysts Worldwide

With roots that trace back to 1911, National Analysts is on record as the world's oldest market research organization, and today conducts hundreds of studies each year to help companies of all kinds evaluate and manage the health of their brands. From its headquarters in downtown Philadelphia, the firm's staff of 73 provides worldwide strategic research and consulting support to industry sectors that include pharmaceuticals and biotechnology, information technology, transport, financial services, and consumer products. More information is available at: http://www.nationalanalysts.com/.

About Quest Diagnostics

Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: http://www.questdiagnostics.com/.

The statements in this press release that are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results and outcomes to be materially different. Certain of these risks and uncertainties may include, but are not limited to, competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors described in the Quest Diagnostics Incorporated's most recent Form 10-K and subsequent SEC filings.
© 2007 PR Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.